There are about 106 peptide and nanobody drug conjugates in active development, and around 63% of them are still preclinical, according to a 2026 Citeline analysis of Pharmaprojects data.¹ For most of ...
BURLINGAME, Calif., June 27, 2011 /PRNewswire/ -- Redwood Bioscience, Inc. announced today that it has secured funding from Takeda Ventures, Inc. ("TVI") to further develop the Company's precision ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results